English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Anal cancer is a rare clinical disease with the incidence rate of 1–2/10 million, while it is about 3–4 times that of perianal cancer (1). Surgery has been the standard treatment for anal cancer in the past, that means performing complete resection on patients’ perineum and anus, making an abdominal wall of a permanent fistula. In 1974, Nigro et al. (2) first reported concurrent chemoradiotherapy for the treatment of anal cancer, it’s become the standard treatment for anal cancer (3). Furthermore, previous studies, such as UKCCCR, RTOG8704/ECOG1289, have established that 5 fluorouracil (5-FU)/mitomycin (MMC) Original Article

Preliminary results on anal cancer by applying intensity modulated radiotherapy and synchronous capecitabine chemotherapy simultaneously